Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -79.86% is 95% below its 5-year average of -41.02%, near the low end of its 5-year range (-80.71%–-19.53%).
6.06% below its 12-month average of -75.29%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.38%.
RETURN ON ASSETS (ROA)
-79.86%
RETURN ON ASSETS (ROA) AVG TTM
-75.29%
RETURN ON ASSETS (ROA) AVG 3Y
-50.35%
RETURN ON ASSETS (ROA) AVG 5Y
-41.02%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.06%
CURRENT VS 3Y AVG
-58.61%
CURRENT VS 5Y AVG
-94.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.47%
median of 734 covered companies
CURRENT VS SECTOR MEDIAN
-162.09%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$215.15M
Return on Assets (ROA)
-79.86%
TTM Avg
-75.29%
3Y Avg
-50.35%
5Y Avg
-41.02%
Market Cap
$214.63M
Return on Assets (ROA)
21.17%
TTM Avg
16.86%
3Y Avg
29.92%
5Y Avg
34.25%
Market Cap
$214.34M
Return on Assets (ROA)
15.00%
TTM Avg
14.43%
3Y Avg
-2.68%
5Y Avg
-18.26%
Market Cap
$214.21M
Return on Assets (ROA)
-31.94%
TTM Avg
-71.44%
3Y Avg
-59.77%
5Y Avg
-50.19%
Market Cap
$213.22M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$216.59M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$209.49M
Return on Assets (ROA)
-48.31%
TTM Avg
-30.88%
3Y Avg
-28.11%
5Y Avg
-28.36%
Market Cap
$223.62M
Return on Assets (ROA)
-28.91%
TTM Avg
-2.34%
3Y Avg
-20.04%
5Y Avg
-20.00%
Market Cap
$206.04M
Return on Assets (ROA)
18.34%
TTM Avg
16.50%
3Y Avg
12.68%
5Y Avg
11.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $215.15M | -79.86% | -75.29% | -50.35% | -41.02% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.63M | 21.17% | 16.86% | 29.92% | 34.25% |
| Niagen Bioscience Inc (NAGE)vs › | $214.34M | 15.00% | 14.43% | -2.68% | -18.26% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.21M | -31.94% | -71.44% | -59.77% | -50.19% |
| Compugen Ltd. (CGEN)vs › | $213.22M | 25.43% | 5.08% | -10.27% | -14.74% |
| Alector, Inc. (ALEC)vs › | $216.59M | -58.10% | -37.08% | -28.02% | -25.91% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $209.49M | -48.31% | -30.88% | -28.11% | -28.36% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.62M | -28.91% | -2.34% | -20.04% | -20.00% |
| Pro-Dex, Inc. (PDEX)vs › | $206.04M | 18.34% | 16.50% | 12.68% | 11.55% |
| Electra Therapeutics Inc. (ETRA)vs › | $202.26M | N/A | N/A | N/A | N/A |
ROA
-79.9%
ROE
-106.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -80.71% |
| 2024-12-31 | -69.88% |
| 2023-12-31 | -31.28% |
| 2022-12-31 | -19.53% |
| 2021-12-31 | -22.19% |
| 2020-12-31 | -22.51% |
| 2019-12-31 | -23.28% |
